UK markets closed

BBIO Aug 2024 40.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.4000-0.4000 (-22.22%)
At close: 02:24PM EDT
Full screen
Previous close1.8000
Open1.4000
Bid0.8500
Ask2.2500
Strike40.00
Expiry date2024-08-16
Day's range1.4000 - 1.4000
Contract rangeN/A
Volume5
Open interest6.45k
  • GlobeNewswire

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on June 6, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 18 new employees in restricted stock units for an aggregate of 90,591 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restri

  • GlobeNewswire

    BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

    PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO of BridgeBio, will present at the Goldman Sachs Annual Global Healthcare Conference in Miami, FL on Wednesday, June 12 at 3:20 pm EDT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” pa

  • Investor's Business Daily

    BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug

    BridgeBio stock gave up gains midday Tuesday after releasing a Phase 2 study on a growth disorder treatment.